Stroke Therapeutics Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

The Stroke Therapeutics Market is segmented by Type (Ischemic Stroke, Hemorrhagic Stroke), by Treatment (Tissue Plasminogen Activators (TPA), Anticoagulants, Antiplatelets, Others), by End User (Hospitals, Clinics, Others) and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Stroke Therapeutics Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 4.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The stroke therapeutics market is projected to register a CAGR of 4.5% during the forecast period, 2022-2027.

Due to the presence of a huge stroke patient base across the world, there is a need for innovative and safe stroke treatment. Currently, only Tissue Plasminogen Activators (TPA) therapy is approved for stroke treatment. Additionally, surgery and removing clots by using a stent retriever are some of the other options available to recover from the stroke. Anti-platelets, anti-coagulants, and anti-convulsant are utilized for the further management of stroke. Covid-19 has significantly impacted the overall healthcare industry. Though it does not directly impact the stroke therapy market, however, there was a disruption in the supply chain of diagnostic & treatment devices and therapeutics. Additionally, many industry players reduced their investment in further development of innovative therapy due to financial losses during the Covid-19 period.

There is a huge population with high cholesterol, high blood pressure, obesity, diabetes, and cardiovascular diseases due to a sedentary lifestyle, and these are the key risk factors for stroke. According to data published by World Stroke Organization (WSO) in 2022, About 12 million (12,224,551) people experienced a stroke in 2019. The organization stated that there are more than 12.2 million new strokes each year, and globally, one in four people after 25 years of age experience a stroke in their lifetime. Hence, the increasing burden of patients globally is expected to drive market growth.

Patent expiry of branded drugs in recent years may impede the therapeutics market growth. For instance, Xarelto’s (Rivaroxaban) US7585860 patent expired in December 2020, and the US7585860 patent is expected to expire by June 2022. Already, Breckenridge, Aurobindo, Hec Pharma, Invagen, Mylan, SigmaPharma, Microlabs, Torrent, Sun (Taro), Teva, Prinston Pharma, Alembic, Macleods, Lupin, and Accord (Intas) filed Abbreviated New Drug Application (ANDA) for the same drug. Hence, the entry of several generic is likely to increase pricing pressure on the market players, and this factor may hamper the market growth.

Scope of the Report

As per the scope of this report, stroke is a condition in which the supply of blood is reduced or blocked completely to the brain, and this is either due to clots or rupturing of the blood vessel in the brain. The stroke therapeutics market is segmented by Type (Ischemic Stroke, Hemorrhagic Stroke), By Treatment (Tissue Plasminogen Activators (TPA), Anticoagulants, Antiplatelets, Others), By End User (Hospitals, Clinics, Others), and by Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values (in USD million) for the above segments.

By Type
Ischemic Stroke
Hemorrhagic Stroke
By Treatment
Tissue Plasminogen Activators (TPA)
By End User
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Tissue Plasminogen Activators (TPA) Dominated in the Market and is Expected to Hold Dominance during the Forecast Period

Tissue plasminogen activator is an effective blood thinner and is approved for the treatment of stroke. It improves the chances of recovering. Several studies observed that patients who receive tissue plasminogen activator during their ischemic stroke are more likely to recover completely or have fewer chances of disability than those who do not consume the drug. Hence, for all patients with ischemic stroke, a tissue plasminogen activator is a first-line therapy to treat.

Activase and Tenecteplase are tissue plasminogen activators manufactured by using recombinant technology and hence named an r-tPA. Availability of products, investment by industry players for commercialization of products, and improving healthcare access in developing countries are some of the key factors driving the market growth. Additionally, several countries' stroke awareness programs support efforts to enhance the utilization of tissue plasminogen activators in eligible stroke patients and thereby improve the outcome of treatment. For instance, the National Institute of Neurological Disorders and Stroke (NINDS) launched a public awareness campaign in the U.S. in 2001 to assist people in recognizing the early signs and symptoms of a stroke. The institute also spreads awareness about the benefits of early treatment through tissue plasminogen activators. Such awareness and educational programs help to improve the utilization of tissue plasminogen activators among patients as soon as their symptoms start.

In January 2022, Thrombolytic Science, LLC was granted a second patent by the United States Patent and Trademark Office for the innovative treatment of ischemic stroke through the use of fibrinolytic enzymes, tissue plasminogen activator, tPA, and urokinase plasminogen activator, uPA. The recent patent approval will pave the way for the development of tissue plasminogen activator-based treatment of stroke, which will likely add to the market growth.

However, patent expiry and entry of Clot-retrieval devices are some of the factors that may restrain the tissue plasminogen activator market growth during the forecast period. For instance, several studies showed that clot retrieval devices are effective in treating clots in large arteries. However, a small artery tissue plasminogen activator is still a preferred treatment.

Leading Stroke Risk Factors in the World

North America Held a Maximum Share in the Market and Expected to Dominate the Market during the Forecast Period

The United States contributed maximum in the North America region in 2021 and is responsible for the dominance of the region across the world. Advanced healthcare infrastructure, well-equipped hospitals, and availability of point of care services are responsible for the maximum demand of drugs for stroke from the United States. Stroke is a condition where treatment must be given as early as possible after the onset of symptoms and hence the availability of quick treatment is a key factor responsible for the high survival rate in the United States. According to the statistics published by the Centers for Disease Control and Prevention (CDC) in April 2022, more than 795,000 Americans have strokes. From which 610,000 are found to be new cases each year. Statistics also showed that Stroke is one of the leading causes of death in the United States and every 40 seconds, someone from the United States has a stroke. This huge patient base and ease in accessing advanced treatment are responsible for the major share of the region across the globe.

North America is expected to observe the same dominance during the forecast period due to development of innovative therapies, local presence of major industry players, and entry of new therapies. In November 2020, the United States Food and Drug Administration approved AstraZeneca’s Brilinta to reduce further risk of stroke in an acute ischaemic stroke. The drug works by inhibiting platelet activation mechanism.

Stroke Therapeutics Market Growth

Competitive Landscape

The stroke therapeutics market is fragmented, competitive, and consists of several major players. Patent expiry of major drugs is responsible for the entry of several generic drugs into the market, and thereby competition in the market increases. AstraZeneca, Amgen Inc., Bristol-Myers Squibb Company, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Merck and Co. Inc., Johnson and Johnson Inc., Pfizer Inc., Sanofi SA, Daiichi Sankyo Company, Limited, and Biogen Inc. are some of the key operating players in the stroke therapeutics market.

Recent Development

In May 2022, researchers at the Osaka Metropolitan University are studying robotic therapy as an effective therapy during the chronic stage of stroke recovery. If widely adopted, robot therapy could improve care for stroke patients while being cost-effective and requiring minimal therapeutic staff guidance.

In April 2022, the United States National Institute of Health funded a USD 1.8 million project to use artificially grown, simplified mini-organs to create medicine that targets brain cells damaged by stroke. The project focuses on the creation of brain-like miniature organs, from which the particles naturally released could be harvested for medicine production.

Table of Contents


    1. 1.1 Study Assumptions & Market Defination

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Investment by Market Players for the Development of New Therapy and Advanced Technology

      2. 4.2.2 Increasing Number of Stroke Patients

    3. 4.3 Market Restraints

      1. 4.3.1 Entry of Various Generic Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type

      1. 5.1.1 Ischemic Stroke

      2. 5.1.2 Hemorrhagic Stroke

    2. 5.2 By Treatment

      1. 5.2.1 Tissue Plasminogen Activators (TPA)

      2. 5.2.2 Anticoagulants

      3. 5.2.3 Antiplatelets

      4. 5.2.4 Others

    3. 5.3 By End User

      1. 5.3.1 Hospitals

      2. 5.3.2 Clinics

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc.

      2. 6.1.2 Bristol-Myers Squibb Company

      3. 6.1.3 Bayer AG

      4. 6.1.4 Boehringer Ingelheim International GmbH

      5. 6.1.5 F. Hoffmann La Roche Ltd.

      6. 6.1.6 Merck and Co. Inc.

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Sanofi SA

      9. 6.1.9 Daiichi Sankyo Company, Limited

      10. 6.1.10 Biogen Inc.

      11. 6.1.11 Johnson & Johnson

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Stroke Therapeutics Market market is studied from 2019 - 2027.

The Global Stroke Therapeutics Market is growing at a CAGR of 4.5% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, F. Hoffmann La Roche Ltd., Johnson & Johnson, Pfizer Inc are the major companies operating in Global Stroke Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!